Granahan Investment Management LLC lowered its position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) by 39.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 522,786 shares of the company's stock after selling 338,647 shares during the period. Granahan Investment Management LLC owned approximately 1.50% of 908 Devices worth $1,150,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Deutsche Bank AG raised its stake in shares of 908 Devices by 1,159.4% in the fourth quarter. Deutsche Bank AG now owns 99,239 shares of the company's stock worth $218,000 after purchasing an additional 91,359 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in 908 Devices by 49.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 85,860 shares of the company's stock valued at $189,000 after acquiring an additional 28,263 shares during the period. Bank of America Corp DE lifted its stake in 908 Devices by 190.9% during the 4th quarter. Bank of America Corp DE now owns 94,753 shares of the company's stock valued at $208,000 after acquiring an additional 62,179 shares during the period. Jane Street Group LLC boosted its holdings in shares of 908 Devices by 118.9% during the 4th quarter. Jane Street Group LLC now owns 113,890 shares of the company's stock valued at $251,000 after acquiring an additional 61,851 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of 908 Devices by 7.5% in the fourth quarter. Northern Trust Corp now owns 200,764 shares of the company's stock worth $442,000 after acquiring an additional 14,087 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.
908 Devices Price Performance
NASDAQ:MASS opened at $5.63 on Friday. 908 Devices Inc. has a one year low of $1.81 and a one year high of $7.48. The business has a fifty day moving average price of $4.44 and a 200-day moving average price of $3.22. The firm has a market capitalization of $201.22 million, a price-to-earnings ratio of -3.18 and a beta of 0.26.
Wall Street Analysts Forecast Growth
MASS has been the topic of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of 908 Devices in a report on Saturday. Stephens restated an "overweight" rating and issued a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.33.
View Our Latest Research Report on MASS
About 908 Devices
(
Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
Want to see what other hedge funds are holding MASS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 908 Devices Inc. (NASDAQ:MASS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
